388 related articles for article (PubMed ID: 28516890)
81. [Tocilizumab in rheumatoid arthritis].
Rueda Gotor J; Blanco Alonso R
Reumatol Clin; 2011 Mar; 6S3():S29-32. PubMed ID: 21794769
[TBL] [Abstract][Full Text] [Related]
82. Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients.
Lee SJ; Park W; Park SH; Shim SC; Baek HJ; Yoo DH; Kim HA; Lee SK; Leee YJ; Park YE; Cha HS; Park JK; Lee EY; Lee EB; Song YW
J Immunol Res; 2015; 2015():487230. PubMed ID: 25922848
[TBL] [Abstract][Full Text] [Related]
83. Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial.
Bazzichi L; Nacci F; Sinigaglia L; Bianchino L; Caporali R
Clin Rheumatol; 2019 Mar; 38(3):841-849. PubMed ID: 30421069
[TBL] [Abstract][Full Text] [Related]
84. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.
Genovese MC; Rubbert-Roth A; Smolen JS; Kremer J; Khraishi M; Gómez-Reino J; Sebba A; Pilson R; Williams S; Van Vollenhoven R
J Rheumatol; 2013 Jun; 40(6):768-80. PubMed ID: 23457383
[TBL] [Abstract][Full Text] [Related]
85. Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study.
Balsa A; Tovar Beltrán JV; Cáliz Cáliz R; Mateo Bernardo I; García-Vicuña R; Rodríguez-Gómez M; Belmonte Serrano MA; Marras C; Loza Cortina E; Pérez-Pampin E; Vila V
Rheumatol Int; 2015 Sep; 35(9):1525-34. PubMed ID: 25773655
[TBL] [Abstract][Full Text] [Related]
86. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
Smolen JS; Aletaha D
Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
[TBL] [Abstract][Full Text] [Related]
87. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Ueki Y; Migita K; Mizokami A; Origuchi T; Aoyagi K; Eguchi K
Mod Rheumatol; 2011 Aug; 21(4):365-9. PubMed ID: 21229375
[TBL] [Abstract][Full Text] [Related]
88. Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan.
Yamamoto K; Goto H; Hirao K; Nakajima A; Origasa H; Tanaka K; Tomobe M; Totsuka K
J Rheumatol; 2015 Aug; 42(8):1368-75. PubMed ID: 26034149
[TBL] [Abstract][Full Text] [Related]
89. Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab.
Hoshi D; Nakajima A; Shidara K; Seto Y; Tanaka E; Taniguchi A; Momohara S; Yamanaka H
Mod Rheumatol; 2013 Nov; 23(6):1205-10. PubMed ID: 23456321
[TBL] [Abstract][Full Text] [Related]
90. Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data.
Paul SK; Montvida O; Best JH; Gale S; Pethoe-Schramm A; Sarsour K
Semin Arthritis Rheum; 2018 Feb; 47(4):478-484. PubMed ID: 28947313
[TBL] [Abstract][Full Text] [Related]
91. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice.
Kaufmann J; Feist E; Roske AE; Schmidt WA
Clin Rheumatol; 2013 Sep; 32(9):1347-55. PubMed ID: 23703358
[TBL] [Abstract][Full Text] [Related]
92. Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study.
Gardette A; Ottaviani S; Sellam J; Berenbaum F; Lioté F; Meyer A; Sibilia J; Fautrel B; Palazzo E; Dieudé P
Clin Rheumatol; 2016 Apr; 35(4):857-61. PubMed ID: 26801332
[TBL] [Abstract][Full Text] [Related]
93. Efficacy and tolerability of six-week extended dosing interval with tocilizumab therapy in a prospective cohort as remission maintenance in patients with rheumatoid arthritis.
Kikuchi J; Kondo T; Shibata A; Sakai R; Okada Y; Chino K; Okuyama A; Kurasawa T; Takei H; Amano K
Mod Rheumatol; 2018 May; 28(3):444-451. PubMed ID: 28849709
[TBL] [Abstract][Full Text] [Related]
94. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.
Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2019; 13():57-70. PubMed ID: 30587928
[TBL] [Abstract][Full Text] [Related]
95. Remission in early, aggressive rheumatoid arthritis: a multicentre prospective observational Italian study ARPA (Artrite Reumatoide Precoce Aggressiva).
Ceccarelli F; Perricone C; Trotta F; Cuomo G; Pellerito R; Bagnato G; Salaffi F; Caporali R; Cutolo M; Galeazzi M; Fiocco U; Lapadula G; Bombardieri S; Bianchi G; Gorla R; Giardina AR; Gallo G; Giardino AM; Valesini G;
Clin Exp Rheumatol; 2013; 31(3):341-9. PubMed ID: 23380023
[TBL] [Abstract][Full Text] [Related]
96. Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data.
Nakashima Y; Kondo M; Fukuda T; Harada H; Horiuchi T; Ishinishi T; Jojima H; Kuroda K; Miyahara H; Maekawa M; Nishizaka H; Nagamine R; Nakashima H; Otsuka T; Shono E; Suematsu E; Shimauchi T; Tsuru T; Wada K; Yoshizawa S; Yoshizawa S; Iwamoto Y
Mod Rheumatol; 2014 Mar; 24(2):258-64. PubMed ID: 24593201
[TBL] [Abstract][Full Text] [Related]
97. Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.
Iwamoto N; Fukui S; Umeda M; Nishino A; Nakashima Y; Suzuki T; Horai Y; Nonaka F; Okada A; Koga T; Kawashiri SY; Fujikawa K; Aramaki T; Ichinose K; Hirai Y; Tamai M; Nakamura H; Terada K; Nakashima M; Mizokami A; Origuchi T; Eguchi K; Ueki Y; Kawakami A
Mod Rheumatol; 2016 Sep; 26(5):662-6. PubMed ID: 26708444
[TBL] [Abstract][Full Text] [Related]
98. Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort.
Baganz L; Richter A; Kekow J; Bussmann A; Krause A; Stille C; Listing J; Zink A; Strangfeld A
Rheumatol Int; 2018 Apr; 38(4):579-587. PubMed ID: 29143933
[TBL] [Abstract][Full Text] [Related]
99. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study.
Otsuka Y; Kiyohara C; Kashiwado Y; Sawabe T; Nagano S; Kimoto Y; Ayano M; Mitoma H; Akahoshi M; Arinobu Y; Niiro H; Akashi K; Horiuchi T
PLoS One; 2018; 13(4):e0196368. PubMed ID: 29694426
[TBL] [Abstract][Full Text] [Related]
100. Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis.
Wang J; Devenport J; Low JM; Yu D; Hitraya E
Arthritis Care Res (Hoboken); 2016 Jun; 68(6):882-5. PubMed ID: 26473986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
